Developer docs
API playgroundTry for free, no card

Search company profiles

Promaxo

Full company profile

uuid0000heo

Namestring
Promaxo
Legal namestring
Promaxo Holdings, Inc.
Websiteurl
promaxo.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Promaxo Holdings, Inc. is a privately held medical imaging, robotics, and AI company founded in 2016 and headquartered in Oakland, California. The company develops and commercializes a portable low-field MRI platform designed for point-of-care use in urology practices and ambulatory surgery centers, with FDA 510(k) clearance (K230123) for MRI-guided prostate biopsy — the first such clearance in the United States for a portable low-field MRI in this indication. The core technology combines a miniaturized MRI scanner using a patented pseudo-birdcage coil architecture with complementary AI-driven lesion localization and robotic needle guidance modules (the latter two are not yet FDA cleared for commercial use). The platform is intended to allow urologists to perform MRI-guided prostate biopsies in-office, eliminating the need to refer patients to external imaging centers.

The company's product portfolio consists of the Promaxo MRI System (core, FDA-cleared), MRI-Guided Biopsy procedures, AI-Driven Insights (lesion localization/targeting optimization, pending FDA clearance), Robotics (live MR-guided needle guidance, pending FDA clearance), and MRI-Targeted Treatment (therapeutic intervention add-on). Revenue mechanics are anchored on direct enterprise sales of MRI hardware to urology practices, ASCs, and hospital systems, supplemented by recurring service and support contracts; pricing is quote-based and not publicly disclosed. Go-to-market relies on enterprise field sales, demo scheduling, conference presence (e.g., AUA 2026), and a multi-channel digital presence (LinkedIn, YouTube, X, Facebook).

The company has raised approximately $129M+ across multiple funding rounds spanning 2017 through 2026, including 2024 and 2026 Form D exempt offerings with participation from over 100 investors. Strategic backers include Zynext Ventures (Zydus Lifesciences VC arm), Spark Growth Ventures, MicroPort Scientific, Kineticos Life Sciences, and surgical robotics pioneer Fred Moll, who serves as a strategic advisor. The company operates exclusively in the United States and has 51-100 employees.

Short descriptiontext

Promaxo develops a portable low-field MRI platform with AI lesion localization and robotic needle guidance for point-of-care prostate biopsy in urology practices, ambulatory surgery centers, and hospitals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOakland, United States
HQ citystring
Oakland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
MRI imaging systems, prostate biopsy guidance, medical robotics, point-of-care diagnostics, urology medical devices
Industry2 codes
PRIMARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging Equipment
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1MRI Hardware Sales
TypeHardware Sales
Description

Sale of the Promaxo MRI System, a portable low-field MRI device for point-of-care prostate biopsy procedures. The FDA 510(k) cleared system is sold directly to urology practices, ASCs, and hospitals.

promaxo.com
2Service and Support
TypeSubscription Recurring
Description

Ongoing service, maintenance, and support for installed MRI systems, likely representing recurring revenue from existing customer base.

promaxo.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Promaxo develops and sells a portable, low-field point-of-care MRI system (FDA 510(k) cleared, K230123) for MRI-guided prostate biopsy in urology practices, ambulatory surgery centers, and hospitals. The platform combines the MRI scanner with AI-driven lesion localization and robotic needle guidance under live MR imaging to enable targeted prostate biopsy and treatment without referring patients to dedicated imaging centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First in US FDA clearance for prostate biopsy and treatment using portable MRI
+1 more record
Product overview1 text field

Promaxo offers a point-of-care MR guidance platform for prostate biopsy, integrating MRI imaging, AI-driven analytics, and robotics into a unified system. The core offering is the Promaxo MRI System (FDA 510(k) cleared), supplemented by the MRI-Guided Biopsy module for procedural guidance, AI-Driven Insights for lesion localization and targeting optimization, Robotics for precision needle guidance, and MRI-Targeted Treatment for point-of-care interventions. The platform is designed for urologists and can be installed at ambulatory surgery centers (ASCs) and hospitals.

Product and service3 records
1Promaxo MRI System
CategoryMedical Imaging Equipment
Description

Portable, low-field point-of-care MRI system FDA 510(k) cleared (K230123) for MRI-guided prostate biopsy. Sold to urology practices, ambulatory surgery centers, and hospitals.

2MRI-Guided Biopsy
CategoryClinical Procedures
Description

Procedure offering for guided prostate biopsies performed at the point of care using real-time MRI imaging for precise needle placement and tissue sampling. For urologists and ASCs.

3MRI-Targeted Treatment
CategoryClinical Procedures
Description

Targeted treatment capability delivered at the point of care using MRI-guided interventions for prostate care. For urology practices and hospitals.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Promaxo

Medical Imaging Equipmentpromaxo.com

Promaxo develops a portable low-field MRI platform with AI lesion localization and robotic needle guidance for point-of-care prostate biopsy in urology practices, ambulatory surgery centers, and hospitals.

What Promaxo does

Promaxo Holdings, Inc. is a privately held medical imaging, robotics, and AI company founded in 2016 and headquartered in Oakland, California. The company develops and commercializes a portable low-field MRI platform designed for point-of-care use in urology practices and ambulatory surgery centers, with FDA 510(k) clearance (K230123) for MRI-guided prostate biopsy — the first such clearance in the United States for a portable low-field MRI in this indication. The core technology combines a miniaturized MRI scanner using a patented pseudo-birdcage coil architecture with complementary AI-driven lesion localization and robotic needle guidance modules (the latter two are not yet FDA cleared for commercial use). The platform is intended to allow urologists to perform MRI-guided prostate biopsies in-office, eliminating the need to refer patients to external imaging centers.

The company's product portfolio consists of the Promaxo MRI System (core, FDA-cleared), MRI-Guided Biopsy procedures, AI-Driven Insights (lesion localization/targeting optimization, pending FDA clearance), Robotics (live MR-guided needle guidance, pending FDA clearance), and MRI-Targeted Treatment (therapeutic intervention add-on). Revenue mechanics are anchored on direct enterprise sales of MRI hardware to urology practices, ASCs, and hospital systems, supplemented by recurring service and support contracts; pricing is quote-based and not publicly disclosed. Go-to-market relies on enterprise field sales, demo scheduling, conference presence (e.g., AUA 2026), and a multi-channel digital presence (LinkedIn, YouTube, X, Facebook).

The company has raised approximately $129M+ across multiple funding rounds spanning 2017 through 2026, including 2024 and 2026 Form D exempt offerings with participation from over 100 investors. Strategic backers include Zynext Ventures (Zydus Lifesciences VC arm), Spark Growth Ventures, MicroPort Scientific, Kineticos Life Sciences, and surgical robotics pioneer Fred Moll, who serves as a strategic advisor. The company operates exclusively in the United States and has 51-100 employees.

Promaxo firmographics

Firmographics
Name
Promaxo
Legal name
Promaxo Holdings, Inc.
Website
https://promaxo.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Promaxo develops a portable low-field MRI platform with AI lesion localization and robotic needle guidance for point-of-care prostate biopsy in urology practices, ambulatory surgery centers, and hospitals.
Ownership category
akta.pro rank

Promaxo industry classification

Industry
Product category
Medical Imaging Equipment
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • MRI imaging systems
  • Prostate biopsy guidance
  • Medical robotics
  • Point-of-care diagnostics
  • Urology medical devices

Where Promaxo is headquartered

Location

Headquarters

HQ city
Oakland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Promaxo business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. MRI Hardware Sales: Sale of the Promaxo MRI System, a portable low-field MRI device for point-of-care prostate biopsy procedures. The FDA 510(k) cleared system is sold directly to urology practices, ASCs, and hospitals.
  2. Service and Support: Ongoing service, maintenance, and support for installed MRI systems, likely representing recurring revenue from existing customer base.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Promaxo product offering

Product offering

Core offering

Promaxo develops and sells a portable, low-field point-of-care MRI system (FDA 510(k) cleared, K230123) for MRI-guided prostate biopsy in urology practices, ambulatory surgery centers, and hospitals. The platform combines the MRI scanner with AI-driven lesion localization and robotic needle guidance under live MR imaging to enable targeted prostate biopsy and treatment without referring patients to dedicated imaging centers.

Product overview

Promaxo offers a point-of-care MR guidance platform for prostate biopsy, integrating MRI imaging, AI-driven analytics, and robotics into a unified system. The core offering is the Promaxo MRI System (FDA 510(k) cleared), supplemented by the MRI-Guided Biopsy module for procedural guidance, AI-Driven Insights for lesion localization and targeting optimization, Robotics for precision needle guidance, and MRI-Targeted Treatment for point-of-care interventions. The platform is designed for urologists and can be installed at ambulatory surgery centers (ASCs) and hospitals.

Differentiator

Problem solved

Functional benefit

Products and services

  • Promaxo MRI System Portable, low-field point-of-care MRI system FDA 510(k) cleared (K230123) for MRI-guided prostate biopsy. Sold to urology practices, ambulatory surgery centers, and hospitals.
  • MRI-Guided Biopsy Procedure offering for guided prostate biopsies performed at the point of care using real-time MRI imaging for precise needle placement and tissue sampling. For urologists and ASCs.
  • MRI-Targeted Treatment Targeted treatment capability delivered at the point of care using MRI-guided interventions for prostate care. For urology practices and hospitals.

Quantifiable outcome

  • First in US FDA clearance for prostate biopsy and treatment using portable MRI
  • +1 more outcomes

Companies that use Promaxo

Customer profile

Segments3 records

Ideal customer profiles3 records

Promaxo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Promaxo partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Promaxo competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Promaxo social profiles

Digital presence

Promaxo compliance and trust

Trust signal

Compliance1 record

Promaxo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Promaxo leadership team

Management profile

Number of profiles

Profiles6 records

Promaxo funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Promaxo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Promaxo

What does Promaxo do?

Promaxo develops and sells a portable, low-field point-of-care MRI system (FDA 510(k) cleared, K230123) for MRI-guided prostate biopsy in urology practices, ambulatory surgery centers, and hospitals. The platform combines the MRI scanner with AI-driven lesion localization and robotic needle guidance under live MR imaging to enable targeted prostate biopsy and treatment without referring patients to dedicated imaging centers.

Is Promaxo a public or private company?

Promaxo is a private company. It is classified as venture growth investor backed and is currently operating.

When was Promaxo founded?

Promaxo was founded in 2016. It employs 51 to 100 people.

Where is Promaxo based?

Promaxo is headquartered in Oakland, United States, in the North America region.

How does Promaxo make money?

Two revenue lines are on record. MRI Hardware Sales are the primary driver. The others are service and Support.

Does Promaxo have an API?

No public API is recorded for Promaxo.

What industry is Promaxo in?

Promaxo's product category is Medical Imaging Equipment. Its primary akta.pro industry code is HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizPromaxo Raises Equity Funding, Gets $100M Credit Facility to Expand MRI-Guided Cancer PlatformPromaxo closed its Series C financing and secured a $100 million credit facility to expand its MRI-guided prostate cancer platform. The company cites a $10 billion U.S. market for prostate screening and treatment, with over 2 million biopsies annually. It is pursuing additional regulatory clearances for its robotic and AI tools.Medical BuyerPromaxo closes Series C financingPromaxo closed its Series C financing with participation from New Science Ventures and Amara Ventures, plus a $100M credit facility. The capital will support expanded manufacturing, backlog reduction, and new regulatory filings. Promaxo is pursuing FDA clearance for its robotic platform and AI-based cancer risk-scoring tool.The future of tradingPromaxo secures initial Series C close with New Science Ventures backingPromaxo closed its initial Series C financing on October 22, 2026, with New Science Ventures and Amara Ventures participating, and also closed a $100 million credit facility. The company's portable MRI system has FDA 510(k) clearance for prostate biopsy and treatment. The new capital will support manufacturing expansion, backlog reduction, and new regulatory filings.Startup ResearcherPromaxo Secures Series C Funding and $100 Million Credit FacilityPromaxo closed its Series C round with New Science Ventures and Amara Ventures, plus a $100 million credit facility. The capital will fund manufacturing expansion, backlog reduction, and regulatory filings, including FDA clearance for its robotic platform and AI cancer risk tool. The company aims to expand into adjacent oncology indications.Business & FinancialPromaxo Announces Closing Of Series C Financing And $100M Credit FacilityPromaxo closed its Series C financing and a $100M credit facility, with participation from New Science Ventures and Amara Ventures. The capital will support manufacturing expansion, backlog reduction, and new regulatory filings. The company is pursuing FDA clearance for its robotic platform and AI-based cancer risk-scoring tool.TracxnTop Companies in Magnetic Resonance Imaging Devices (Oct, 2025)This article presents a ranking of top startups in the Magnetic Resonance Imaging devices sector, highlighting companies such as Hyperfine, Openwater, Promaxo, and Fonar. It details their founding years, funding rounds, and specific technological innovations, such as portable MRI systems and wearable diagnostic headsets. The report also notes that an average of two new companies in this field are launched annually over the past decade.The ASCO PostTwo Universities to Develop Incisionless Prostate Cancer Surgery Using MRI and RoboticsCase Western Reserve University and Vanderbilt University have received a $3.7 million grant from the National Cancer Institute to develop an incisionless prostate cancer surgery technique combining robotics and low-field MRI. The project involves adapting Virtuoso Surgical's robot and integrating it with Promaxo’s MRI scanner to enable targeted removal of cancer lesions without traditional incisions. This research aims to improve surgical safety and efficiency by allowing precise treatment of localized prostate cancer.SecSEC FORM DPromaxo, Inc. filed a Form D with the U.S. Securities and Exchange Commission for an exempt offering of equity securities under Rule 506(b). The filing discloses a total offering amount of $57,304,100, with $41,939,728 already sold to 163 investors as of March 25, 2024. The company, incorporated in Delaware and based in Oakland, California, is conducting this private placement without the use of general solicitation.FinSMEsPromaxo Receives Investment from Zynext VenturesPromaxo, an Oakland-based developer of portable low-field MRI systems and minimally invasive robotics, received an undisclosed investment from Zynext Ventures, the VC arm of Zydus Lifesciences. The company will use the funds to expand operations and development efforts. Promaxo's MRI is the first in the USA to receive FDA 510(k) clearance for prostate biopsy and treatment.NewswireZynext Ventures, the VC arm of Zydus Lifesciences, Announces Investment in Promaxo: Pioneering Point-of-Care Medical Imaging and Interventions with Next Generation MRI SystemsZynext Ventures, the venture capital arm of Zydus Lifesciences, announced an investment in Promaxo Inc., a US-based developer of portable low-field MRI systems and minimally invasive robotics. This strategic funding aims to accelerate Promaxo's mission to provide accessible point-of-care imaging and intervention technologies, leveraging its FDA-cleared portable MRI system for prostate procedures.